TECH bio-techne.com: Forward P/S Multiple

Bio-Techne Corporation (TECH) benefits from the conservative approach of scientists when selecting reagents, although the fierce competition for innovation demands colossal R&D expenditures. The forward P/S multiple timeline on the GURU.Markets chart captures this balance, with the value stabilizing at 4.40. The superior purity of its products provides the company with pricing power, allowing it to consistently index product costs without a loss in demand.

bio-techne.com - TECH Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Bio-Techne Inc. (TECH)

- current price and projected stock value:

Stock Price Bio-Techne|TECH - Average Forecast Price

- company stock capitalization data:

Market Capitalization Bio-Techne Inc.|TECH - Business Value

- issuer book value statistics:

Book Value per Share Bio-Techne|TECH - Book Valuation of Business|Market Capitalization to Book Value Ratio bio-techne.com|TECH - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

TECH - Annual Net Income|Future Profit Bio-Techne Corporation|TECH - P/E Multiple|Forward P/E Multiple Techne Corporation|TECH - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bio-Techne Inc.|TECH - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Bio-Techne|TECH - Net earnings per share for the last 12 months|Quarterly EPS earnings growth bio-techne.com|TECH - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Bio-Techne Corporation

- sales volume and revenue indicators:

TECH - Company Sales Volume|Company Future Sales Volume Bio-Techne|TECH - Market Cap to Sales Volume|Forward P/S Multiple Bio-Techne Inc.

Summary company analytics:Bio-Techne (TECH)

Product sample of Bio-Techne Corporation

An investment audit of Bio-Techne Corporation (TECH) requires an analysis of the forward P/S ratio, which compares current market capitalization with projected sales volume to assess the premium paid for future growth. Given its monopoly position in the high-purity reagents segment and its pricing power, this forward price-to-sales ratio on GURU.Markets serves as an indicator of the premium's resilience relative to the business's fundamental metrics.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|BRKR - Market Cap to Expected Sales Ratio|AZTA (Azenta) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Varex Imaging Corp (VREX)|Forward P/S Multiple SMLR|Forward P/S Multiple Butterfly Corp (BFLY)|Price-to-Projected Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Projected Revenue Ratio|NNOX: Forward Price-to-Revenue Multiple|Forward Price to Sales QTRX (Quanterix Corp.)|MASS: Forward P/S Multiple|Market Cap to Future Revenue Ratio CapsoVision (CV)|Price-to-Projected Revenue Ratio MaxCyte, Inc.|RPID - Projected Price to Revenue|Forward Price-to-Revenue Multiple SEER (Seer)|Forward P/S Multiple Hyperfine Inc (HYPR)|Forward P/S Multiple FONR (FONAR Corp)|Market Cap to Expected Sales Ratio Daxor Corp (DXR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)